UnratedDrug recall · FDA · Published March 13, 2026
Endo USA Buprenorphine Injection Recall: Crystallization Risk
Endo USA recalls 5x1mL Buprenorphine injections due to crystallization risk. Affected lots expire 02/2027 and 03/2027. Contact for return instructions.
“Endo USA Buprenorphine Injection Recall: Crystallization Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31434-endo-usa-buprenorphine-injection-recall-crystallization-risk. Based on FDA recall #D-0527-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0527-2026%22&limit=1).
ENDO USA, Inc. voluntarily recalled Buprenorphine Hydrochloride Injection vials on March 13, 2026, due to crystallization identified as Buprenorphine free base, the FDA said. Owners should contact the company for a refund.
How to tell if you have it
Brand: Endo USA
Product: Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials
NDC: 42023-179-05
Lot codes: 84132 (Exp 02/28/2027), 87693 (Exp 03/31/2027)
Quantity: 34,293 vials
The hazard
The recall addresses crystallization in the injection solution, which has been identified as Buprenorphine free base. The FDA classified this Class II recall because use of the product could result in serious adverse health consequences or death.
Context
ENDO USA, Inc. has 4 other recalls on record since November 18, 2024. Other recent recalls of similar products include Par Health Buprenorphine Injection Recall (June 12, 2026), Par Health Recalls Buprenorphine Injections Due to Crystallization (September 8, 2026), and American Regent Epinephrine Injection Recall (August 11, 2026).
How to tell if you have this one
Check for vials labeled 'Buprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only' with lot numbers 84132 or 87693. The expiration dates are 02/28/2027 or 03/31/2027.
Brand
Endo USA
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Vial Details
Look for lot numbers 84132 or 87693 on the vial label with expiration dates 02/28/2027 or 03/31/2027.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “USA Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA published this recall 2 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0527-2026 (March 13, 2026) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0527-2026 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.